Steven Lydeamore has over 30 years of international pharmaceutical experience within Australia, Canada and USA. This includes valuable experience in mergers and acquisitions, finance, business development, sales and marketing, manufacturing, research and development.
Mr Lydeamore spent 11 years working at Canadian global pharmaceutical company Apotex Inc, and four years for Mayne Pharma (USA). He was chief executive of Anatara Lifesciences from December 2018 to June 2022 , during which time the company successfully transitioned from a preclinical to a clinical company following development of a gastrointestinal tract delivery technology from which two products have commenced human clinical trials. Mr Lydeamore left Anatara Lifesciences to become chief executive of Immuron.
